NCT06734013 Transcriptomics as an Aid in the Histological Diagnosis of Acute Rejection After Liver Transplantation
| NCT ID | NCT06734013 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
| Condition | Rejection; Transplant, Liver |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2024-10-17 |
| Primary Completion | 2025-05-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2024-10-17 with a primary completion date of 2025-05-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary objective of this exploratory study is to identify genes associated with acute rejection in liver transplant patients. To this end, a panel of acute rejection indicator genes (both humoral and cell-mediated) will be selected from results published in the literature and applied to biological material derived from biopsies. The secodnary objective is to identify genes associated with the diagnosis of humoral acute rejection and those associated with the diagnosis of cell-mediated acute rejection.
Eligibility Criteria
Inclusion Criteria: * Patients with a diagnosis of post-OLT rejection prior to the visit at which they will be enrolled, with tissue available for RT-PCR investigations * Age ≥ 18 years * Informed consent Exclusion Criteria: * Age \<18 years
Contact & Investigator
Deborah Malvi, MD
PRINCIPAL INVESTIGATOR
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Frequently Asked Questions
Who can join the NCT06734013 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Rejection; Transplant, Liver. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06734013 currently recruiting?
Yes, NCT06734013 is actively recruiting participants. Contact the research team at deborah.malvi@aosp.bo.it for enrollment information.
Where is the NCT06734013 trial being conducted?
This trial is being conducted at Bologna, Italy.
Who is sponsoring the NCT06734013 clinical trial?
NCT06734013 is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. The principal investigator is Deborah Malvi, MD at IRCCS Azienda Ospedaliero-Universitaria di Bologna. The trial plans to enroll 40 participants.